Welcome to our dedicated page for Kymera Therapeutics SEC filings (Ticker: KYMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech can feel like decoding a PhD thesis, especially when Kymera Therapeutics’ 10-K details targeted protein degradation pathways across dozens of pages. If you have ever wondered, “Kymera Therapeutics SEC filings explained simply,” this page was built for you. Stock Titan delivers AI-powered summaries that translate dense science and financial footnotes into clear insights, so you can spot cash-runway metrics, development milestones, and risk factors without poring over every chart.
Whether you need the Kymera Therapeutics annual report 10-K simplified to gauge R&D spend, a Kymera Therapeutics quarterly earnings report 10-Q filing to track collaboration revenue, or a quick brief on that sudden Kymera Therapeutics 8-K material events explained, our platform has it in one place. Real-time alerts surface Kymera Therapeutics Form 4 insider transactions real-time, letting you follow executive stock moves the moment they hit EDGAR. Each document comes with AI context—drug-pipeline timelines, STAT6 trial updates, and cash-burn trends—so understanding Kymera Therapeutics SEC documents with AI becomes second nature.
Investors frequently look for:
- Kymera Therapeutics insider trading Form 4 transactions to gauge management confidence
- Kymera Therapeutics proxy statement executive compensation to evaluate incentives
- Kymera Therapeutics earnings report filing analysis for runway visibility
Kymera Therapeutics (KYMR) filed its Q3 2025 10-Q, highlighting a strong liquidity position and ongoing collaboration-driven revenue. Cash, cash equivalents and marketable securities totaled $978.7 million as of September 30, 2025, supported by a June–July follow-on offering with approximately $288.4 million in aggregate gross proceeds. Total assets were $1.10 billion and stockholders’ equity was $946.3 million.
For Q3 2025, the company reported collaboration revenue of $2.764 million, research and development expense of $74.094 million, and a net loss of $82.175 million (basic and diluted net loss per share $0.94). Year-to-date through Q3, collaboration revenue was $36.341 million, net loss was $224.370 million, and cash used in operating activities was $166.144 million. Deferred revenue was $37.236 million, including $37.2 million from the $40.0 million upfront payment in the Gilead molecular glue degrader agreement, to be recognized over an estimated 1.5 years. Under the Sanofi IRAK4 collaboration, the company recognized $33.6 million year-to-date and remains eligible for up to $975 million in future milestones tied to development, regulatory and commercial events. As of October 31, 2025, common shares outstanding were 71,949,027.
Kymera Therapeutics (KYMR) reported insider transactions by its Chief Executive Officer on 10/29/2025 under a Rule 10b5-1 trading plan dated September 6, 2024. The CEO exercised 30,000 stock options at an exercise price of $2.08 per share and acquired 30,000 shares, then sold 30,000 shares in three trades at weighted average prices of $59.7225, $61.0186, and $61.4576.
The filing notes these sales occurred in multiple transactions within disclosed price ranges. Following the transactions, the reporting person held 660,482 shares of common stock directly. The stock option reported was fully vested and exercisable, and 405,559 derivative securities were beneficially owned following the transactions.
Kymera Therapeutics (KYMR) Form 4: The Chief Medical Officer reported transactions on 10/15/2025 under a Rule 10b5-1 trading plan dated June 2, 2025. He exercised 28,999 stock options at $1.31 and 22,210 options at $2.08, adding shares via option exercises.
He then sold 29,264 shares at a weighted average price of $60.37, 8,963 at $61.4929, 14,896 at $62.7233, and 6,453 at $63.0868. Following these transactions, he beneficially owned 109,992 shares directly.
Kymera Therapeutics (KYMR): insider transaction — The company’s Chief Medical Officer reported multiple trades on 10/13/2025. The officer exercised stock options for 800 shares at $1.31 and 673 shares at $2.08, then sold 3,114 shares at $60. Following these transactions, the officer directly owned 118,359 shares of common stock. The filing notes these trades were made under a Rule 10b5-1 trading plan dated June 2, 2025. The exercised options were fully vested and remain tied to grants expiring on 10/31/2028 and 05/22/2029.
Kymera Therapeutics (KYMR) director reported a Form 4 for Oct 13, 2025: exercised 5,000 stock options at $10.34 and sold 5,000 common shares at a $59.1898 weighted average price under a Rule 10b5-1 plan dated Sept 20, 2024.
Following these transactions, the filing shows 0 shares directly owned and 0 derivative securities remaining.
Bruce N. Jacobs, Chief Financial Officer of Kymera Therapeutics, reported multiple transactions under a Rule 10b5-1 trading plan adopted September 6, 2024. On 09/17/2025 he acquired 79,220 shares of Kymera common stock at $2.08 (via exercise of options) and sold 79,220 shares at a weighted-average price of $50.0048 (sales executed across prices $49.90–$50.25). After the transactions the filing reports 306,629 shares beneficially owned before the sale and 227,409 shares following the sale. The report discloses two stock option transactions with exercise price $2.08 that were fully vested and exercisable, and notes 523 shares were earlier acquired under the employee stock purchase plan on June 2, 2025.
Form 144 filed for Kymera Therapeutics, Inc. (KYMR) reporting a proposed sale of 79,220 shares of common stock through Morgan Stanley Smith Barney LLC on 09/17/2025. The filing shows the shares were acquired the same day by exercise of stock options from the issuer and were paid in cash. The aggregate market value of the shares at the proposed sale is reported as $3,864,351.60 and the company has 71,497,597 shares outstanding per the form. No other securities sales in the past three months are reported and the filer certifies they do not possess undisclosed material adverse information.
Kymera Therapeutics insider transactions by CEO and director Nello Mainolfi on 09/16/2025: The filing shows the exercise of a fully vested stock option with a $2.08 exercise price that converted into 30,000 shares, and an offsetting sale of 30,000 shares at $49. Following these transactions the reporting person beneficially owned 660,482 shares.
The filing notes these trades were executed under a Rule 10b5-1 trading plan adopted September 6, 2024, and the derivative shares underlying the option are fully vested and exercisable with an expiration date of November 13, 2029.
Kymera Therapeutics (KYMR) Form 144 notice reports a proposed sale of 30,000 common shares. The shares are scheduled to be sold through UBS Financial Services on NASDAQ on 09/16/2025 with an aggregate market value of $1,470,000. The filing states 71,497,597 shares outstanding. The 30,000 shares were acquired on 09/16/2025 by exercise of stock options from the issuer and payment was in cash on the same date. The filer reports no securities sold in the past three months and affirms no undisclosed material adverse information.
FAQ
What is the current stock price of Kymera Therapeutics (KYMR)?
What is the market cap of Kymera Therapeutics (KYMR)?
